HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, through its wholly owned subsidiary Probulin Probiotics LLC, is offering products in China. The products are available on Alibaba Group Holding’s Tmall (“Tmall”) Global, the world’s largest cross-border online marketplace, with a reach of more than 750 million potential customers in China, Hong Kong, Macau and Taiwan. Calling the move a tremendous opportunity, the company plans to begin shipping product next week, with products available for purchase beginning March 29, 2021. The company anticipates having its Total Care Immune, Total Care, Daily Care, Women’s Health, Colon Support and My Little Bugs(TM) Total Care Probiotic for Kids offered on the site. Last year health supplements and probiotics were among the most popular categories on the Tmall platform. “Launching in China is a tremendous milestone and an unparalleled opportunity to educate the enormous Chinese market on the many health benefits of probiotics,” said HempFusion co-founder and CEO Dr. Jason Mitchell, N.D. “At Probulin, we stand on integrity, offering only the highest quality products and radical transparency throughout the entire process. We believe Probulin to be the first American company to deliver cold and protected probiotic supplements direct to Chinese consumers. In addition, our scientifically validated MAKTrek(R) 3-D Probiotic Delivery System is designed to protect and nourish the probiotics so that more can arrive alive in the gut. These two distinguishing factors result in a positive influence on the microbiome and overall wellness.”
To view the full press release, visit https://ibn.fm/llEi7
About HempFusion Wellness Inc.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research and HF Labs, to approximately 4,000 retailers across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 46 SKUs (“SKUs”) including tinctures, proprietary FDA Drug Listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in store or online. For more information about the company, visit www.HempFusion.com.
NOTE TO INVESTORS: The latest news and updates relating to CBDHF are available in the company’s newsroom at https://ibn.fm/CBDHF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
